Tag Directory / PHARMACEUTICALS     showing 1–7 of 7


for: Saturday, March 07, 2026



Eli Lilly's new program aims to boost employer coverage of GLP-1s / Endpoints

Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #weightloss #healthcarefinance


Saturday, March 7, 2026, 10:21 pm / permalink 20341 / 16 stories in 3 days


ASCO GU 2026 Highlights: Belzutifan + Lenvatinib and Pembrolizumab in RCC – IUCS / OncoDaily

oncodaily - International Urology Cancer Summit shared a post on LinkedIn: “IUCS Journal Club – Highlights from ASCO GU 2026: Targeting HIF-2α in RCC. This Journal Club session reviews the data from […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology


Saturday, March 7, 2026, 9:22 am / permalink 20321 / 3 stories in 4 days


New FDA bonus pilot to address 'workforce challenges' / Endpoints

Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...

#healthcare #pharmaceuticals #governmentpolicy #biotech #drugdevelopment #fda #healthcarefinance


Saturday, March 7, 2026, 12:23 am / permalink 20312 / 2 stories in 4 days


FDA lifts hold on Intellia trial / Beckers

Ella Jeffries / beckershospitalreview - The FDA has lifted a clinical hold on Intellia Therapeutics’ phase 3 Magnitude trial of nexiguran ziclumeran, or nex-z. The trial was paused Oct. 29 after a patient developed grade 4 liver transaminase elevations and elevated bilirubin following a Sept. 3…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, March 7, 2026, 12:23 am / permalink 20309 / 2 stories in 4 days


Optum Rx, Caremark making ‘significant progress’ in settlement talks with FTC / Healthcare Dive

Rebecca Pifer Parduhn / healthcaredive - It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, after Cigna agreed to a sweeping settlement in the insulin lawsuit last month.

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #healthcarefinance


Saturday, March 7, 2026, 12:23 am / permalink 20308 / 3 stories in 4 days


Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology / MedCity

Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #healthcarefinance #infectiousdisease


Saturday, March 7, 2026, 12:22 am / permalink 20307 / 3 stories in 4 days


Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma / MedCity

Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #healthcarefinance


Saturday, March 7, 2026, 12:22 am / permalink 20306 / 4 stories in 4 days


Back to Top


PHARMACEUTICALS Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.